← Back to screener

Rapport Therapeutics, Inc. RAPP

Rank #1496 · Nasdaq · $1.2B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
47.5
P/E
-15.3
P/B
-46.74
ROE
305.5%
Op. Margin
–%
Debt Ratio
-37%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -15.3x, P/B -46.74x. Ranks in the top 90% of the universe.

Profitability ★★★★★
Excellent

ROE 305.5%. Ranks in the top 1% of the universe.

Safety ★★★★★
Excellent

Debt ratio -37%. Ranks in the top 6% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2024–$-0.0B$-0.0B$-0.0B–-144
2025–$-0.1B$-0.1B$-0.0B–-37

← See the full screener